T here is a growing body of evidence that suggests that immunological mechanisms play a role in cerebral thrombosis and stroke.' Antiphospholipid antibodies (aPL) are linked clinically with thromboembolism and ischemic cerebrovascular disease including transient ischemic attack,23 amaurosis fugax,4-6 acute ischemic encephalopathy,6 multi-infarct dementia,78 and stroke.23 12 It has not been established whether aPL are directly pathogenic and mediators of disease or merely serological epiphenomena, markers of a more fundamental disturbance in coagulation. Pathological studies in patients with aPL and stroke demonstrate a noninflammatory thrombotic occlusion of cerebral vessels.6'13'14 Theories of pathogenesis center around either platelet15'16 or endothelial cell dysfunction. [16] [17] [18] [19] [20] [21] There are suggestions that immunoglobulins in the sera of patients with aPL disrupt the thromboresis-dressed the interaction of aPL with human brain endothelium. We undertook this study to determine if there are immunoglobulins in the sera of patients with aPL and stroke that bind to human brain microvascular endothelial cells.
Subjects and Methods Subjects
Sera from three groups of subjects were included. Group 1 included patients with a history of ischemic cerebrovascular disease who were found on diagnostic evaluation to have aPL: either elevated immunoglobulin G (IgG) anticardiolipin antibodies by enzyme-linked immunosorbent assay (ELISA) or the presence of a lupus anticoagulant. These patients were detected by an ongoing prospective screening for aPL in patients presenting with stroke at the Medical College of Georgia Hospital and its affiliated Veterans Affairs Medical Center or from referrals of patients to the outpatient clinics with known aPL and stroke. This group was further subdivided into patients with systemic lupus erythematosus (SLE) according to the criteria of the American Rheumatism Association criteria22 and those without a defined collagen vascular disorder.
Group 2 included 62 healthy control subjects: donors at a local community blood bank who were age and sex matched for subjects in group 1. Group 3 included patients with acute ischemic stroke without aPL or SLE. These were consecutive patients screened as above and found not to have aPL.
All patients in groups 1 and 3 were examined by a neurologist (one of the authors). Blood was drawn by venipuncture 3 days to 14 months after the index event from patients in group 1 and within 10 days of the ischemic stroke in group 3.
The criteria for aPL positivity was either elevation of IgG anticardiolipin antibody (aCL) by solid-phase ELISA (see below) or the presence of a lupus anticoagulant. Detection of a lupus anticoagulant was by (1) prolongation of the activated partial thromboplastin time, (2) and subsequently trapped on a 40-gm nylon mesh. The microvessels then were treated with a mixture of 1 mg/mL collagenase and dispase (Boehringer-Mannheim) at 37°C overnight. The following morning, the treatment was terminated by washing with M199 and pelleting at 800g and resuspending in M199 with 10% fetal bovine serum (FBS). To isolate endothelial cells, the suspension was layered over a Percoll gradient. Fractions from the gradients were collected into sterile dishes and examined with inverted-phase contrast microscopy. Those dishes containing viable cells were diluted in M199 and centrifuged to remove Percoll. Isolated clumps of endothelial cells then were seeded in 32-mm plates and maintained in M199 with 10% FBS and penicillin (100 gg/mL) and streptomycin (100 gg/ mL). The medium was changed every 2 days. The endothelial cells attached to the bottom of the plate, and 5 to 7 days later, colonies were evident (Fig 1) A known positive and a known negative sample (pooled human sera) was run with every plate. Each test sample was assigned a value in reference to these samples. This value, the ELISA index (El), was derived from the formula 100x(U-N)/(P-N), where U-GD of unknown sample, P=OD of known high positive sample, and N =GD of known negative sample. The intra-assay and interassay coefficients of variation were < 10% when the assay was performed with endothelial cells from the same donor.
Absorption With Cardiolipin Liposomes
Liposomes were prepared according to the methods of Pengo et al. 27 A mixture of cardiolipin, cholesterol, and dicetyl phosphate (molar ratio 10:15:2) in chloroform was dried in a stream of nitrogen. The lipids were resuspended in 1 mL of 0.15 M NaCl by agitation using a vortex mixer; 500 ,uL of patient serum was incubated for 1 hour at 37°C and then overnight at 4°C. After centrifugation, the supernatants were kept as absorbed serum.
Cytotoxicity
Cytotoxicity was measured by a chromium release assay. Human brain endothelial cells were plated and grown to confluence in 24-well Costar plates. After aspiration of the medium and one wash with M199, the cells were incubated overnight with 1 gCi Na`1Cr per well in 10% FCS in M199. The following morning, the wells were again aspirated and washed three times with M199 to remove unincorporated chromium. The wells were then overlaid with 10% patient or control serum in M199 and incubated for 4 to Group 1 was further divided into those patients who had their sera drawn within 10 days of the index ischemic event and those later than 10 days (see Table) . The mean EI±SD was 75±38 in those drawn within 10 days and 49±31 for those drawn later (P=.11). In the subgroup of group 1 without SLE, the El was 56±39 in those drawn early (n=6) and 39±32 in those drawn late (n=6) (P=.44).
To ensure that the increased binding was not specific to any individual endothelial cell line, at least 10 sera from each group were tested on human brain microvascular endothelial cells derived from at least three different donors. In all instances, positive sera (>3 SD above control mean) remained positive and negative sera remained negative.
To 
